Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Subordinate CMBS certificates in over 150 CMBS securitizations
Represented over a dozen different investors in the acquisition of subordinate CMBS certificates in over 150 CMBS securitizations including more
Catastrophic injury services for industrial accident
Represented a truck driver injured when an asphalt silo malfunctioned, spilling molten asphalt into the truck cab and trapping the driver. more
Design, construction, and commissioning of an off-shore oil production facility in Malaysia for worldwide oil and gas organization
Represent a worldwide oil and gas organization with respect to disputes against various EPC contractors retained to perform the design, more
Sale of subsidiary's assets for Blount International Inc.
Represented Blount International Inc., a publicly traded manufacturer of lawn and garden equipment, in the sale of substantially all of the more